DARZALEX — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson DARZALEX — Sales to customers (Note 9) increased by 3.8% to $7.34B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 21.8%, from $6.03B to $7.34B. Over 2 years (FY 2021 to FY 2024), DARZALEX — Sales to customers (Note 9) shows an upward trend with a 63.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition, patent expiration, or shifts in treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific high-growth oncology therapeutic prod...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or key therapeutic assets reported by other major pharmaceutical companies.
jnj_segment_darzalex_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.73B | $2.87B | $3.16B | $4.17B | $3.71B | $3.97B | $4.10B | $4.53B | $5.00B | $5.38B | $5.76B | $6.03B | $6.17B | $6.48B | $7.08B | $7.34B |
| QoQ Change | — | +5.0% | +10.3% | +31.8% | -10.9% | +7.0% | +3.3% | +10.3% | +10.4% | +7.7% | +6.9% | +4.8% | +2.3% | +5.0% | +9.3% | +3.8% |
| YoY Change | — | — | — | — | +36.0% | +38.6% | +29.9% | +22.0% | +25.8% | — | +27.1% | +20.7% | — | +20.3% | +22.9% | +21.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's darzalex — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported darzalex — sales to customers (note 9) of $7.34B in Q3 2025.
- How has Johnson & Johnson's darzalex — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's darzalex — sales to customers (note 9) increased by 21.8% year-over-year, from $6.03B to $7.34B.
- What is the long-term trend for Johnson & Johnson's darzalex — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's darzalex — sales to customers (note 9) has grown at a 63.3% compound annual growth rate (CAGR), from $8.76B to $23.34B.
- What does darzalex — sales to customers (note 9) mean?
- The total revenue earned from sales of a specific oncology drug product.